导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.45% | 1635/4773 |
| 近一周 | 0.76% | 80/5462 |
| 近一月 | 5.61% | 58/5421 |
| 近一季 | 5.14% | 289/5209 |
| 近半年 | 6.05% | 719/4920 |
| 近一年 | 3.32% | 1949/4366 |
| 近两年 | 38.77% | 1946/2954 |
| 近三年 | 47.48% | 578/2253 |
| 成立以来 | 43.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.79% 2908/4961 |
-8.07% 3831/5312 |
- - |
- - |
| 2025 | 10.05% 2837/4813 |
2.47% 1363/3635 |
11.29% 193/4076 |
-8.56% 4049/4524 |
5.54% 433/4813 |
| 2024 | 38.90% 31/3463 |
9.99% 86/2808 |
6.90% 113/3014 |
12.27% 2382/3129 |
5.22% 620/3463 |
| 2023 | -2.59% 592/2656 |
-2.58% 2022/2280 |
2.04% 176/2385 |
4.71% 132/2515 |
-6.42% 1769/2655 |
| 2022 | -4.66% 99/2207 |
2.01% 83/1919 |
-1.32% 1704/2016 |
-8.18% 177/2113 |
3.14% 762/2208 |
| 2021 | -1.08% 780/1822 |
10.17% 45/1255 |
-2.56% 1214/1330 |
-7.20% 1031/1466 |
-0.71% 1269/1822 |
| 2020 | -1.25% 952/1250 |
-14.18% 950/1028 |
1.80% 984/1067 |
3.88% 964/1164 |
8.81% 659/1184 |
| 2019 | - - |
- - |
- - |
-1.30% 643/850 |
6.10% 655/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证银行ETF联接A VS. 长安沪深300非周期A(740101) |